Literature DB >> 24716874

Clinical applications of SPECT/CT after first I-131 ablation in patients with differentiated thyroid cancer.

Shin Young Jeong1, Sang-Woo Lee, Hae Won Kim, Bong-Il Song, Byeong-Cheol Ahn, Jaetae Lee.   

Abstract

OBJECTIVE: This study aimed to determine which thyroid cancer patients would benefit from SPECT/CT in addition to whole-body planar scintigraphy (RxWBS) for the detection and characterization of I-131 focal uptake after first ablation. DESIGN AND PATIENTS: Neck and thoracic SPECT/CT was performed in 187 patients with I-131 focal uptake suggestive of remnant thyroid tissue (Rem group, n = 152) or presumed lymph node (LN) metastases (mLN group, n = 35) on RxWBS. Clinical and pathologic parameters were analysed and compared in patients with and without additional SPECT/CT findings.
RESULTS: wIn the Rem group, SPECT/CT revealed additional occult findings on RxWBS in 13 patients (8·6%). The serum thyroglobulin levels at the time of ablation were significantly higher in patients with additional SPECT/CT findings than in patients without additional findings (4·3 ± 3·4 ng/ml vs 1·6 ± 2·7 ng/ml, P = 0·001). In the mLN group, SPECT/CT demonstrated only remnant thyroid tissues without evidence of lymph node metastasis in 14 (40·0%) patients, whereas in the remaining 21 (60·0%) patients, I-131 uptake was confirmed in the corresponding neck and mediastinal lymph nodes on SPECT/CT.
CONCLUSIONS: Even in the Rem group, additional SPECT/CT could provide useful information for detecting hidden metastasis, especially in patients with high serum thyroglobulin levels. SPECT/CT should be recommended for patients with focal uptake lymph node metastasis on RxWBS.
© 2014 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24716874     DOI: 10.1111/cen.12460

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  13 in total

Review 1.  Controversies in the Management of Low-Risk Differentiated Thyroid Cancer.

Authors:  Megan R Haymart; Nazanene H Esfandiari; Michael T Stang; Julia Ann Sosa
Journal:  Endocr Rev       Date:  2017-08-01       Impact factor: 19.871

2.  Endocrine radionuclide scintigraphy with fusion single photon emission computed tomography/computed tomography.

Authors:  Ka-Kit Wong; Arpit Gandhi; Benjamin L Viglianti; Lorraine M Fig; Domenico Rubello; Milton D Gross
Journal:  World J Radiol       Date:  2016-06-28

Review 3.  SPECT/CT: an update on technological developments and clinical applications.

Authors:  Michael Ljungberg; P Hendrik Pretorius
Journal:  Br J Radiol       Date:  2017-01-16       Impact factor: 3.039

Review 4.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

Review 5.  KSNM60 in Nuclear Endocrinology: from the Beginning to the Future.

Authors:  Chae Moon Hong; Young Jin Jeong; Hae Won Kim; Byeong-Cheol Ahn
Journal:  Nucl Med Mol Imaging       Date:  2022-01-24

6.  Intramedullary Spinal Cord Metastases from Differentiated Thyroid Cancer, a Case Report.

Authors:  Fabio Volpe; Leandra Piscopo; Mariarosaria Manganelli; Maria Falzarano; Federica Volpicelli; Carmela Nappi; Massimo Imbriaco; Alberto Cuocolo; Michele Klain
Journal:  Life (Basel)       Date:  2022-06-09

Review 7.  SPECT/CT in the Treatment of Differentiated Thyroid Cancer.

Authors:  Sang-Woo Lee
Journal:  Nucl Med Mol Imaging       Date:  2017-02-08

Review 8.  Factors Associated with Dose Determination of Radioactive Iodine Therapy for Differentiated Thyroid Cancer.

Authors:  Chae Moon Hong; Byeong-Cheol Ahn
Journal:  Nucl Med Mol Imaging       Date:  2018-05-02

9.  Risk factors for radioactive iodine-avid metastatic lymph nodes on post I-131 ablation SPECT/CT in low- or intermediate-risk groups of papillary thyroid cancer.

Authors:  Chang-Hee Lee; Ji-Hoon Jung; Seung Hyun Son; Chae Moon Hong; Ju Hye Jeong; Shin Young Jeong; Sang-Woo Lee; Jaetae Lee; Byeong-Cheol Ahn
Journal:  PLoS One       Date:  2018-08-17       Impact factor: 3.240

Review 10.  Two decades of SPECT/CT - the coming of age of a technology: An updated review of literature evidence.

Authors:  Ora Israel; O Pellet; L Biassoni; D De Palma; E Estrada-Lobato; G Gnanasegaran; T Kuwert; C la Fougère; G Mariani; S Massalha; D Paez; F Giammarile
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-07-04       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.